Jul '22
Emerald Health Therapeutics, Inc. Reports 2021 Year-End Results and Corporate Update
Company also provides bi-weekly MCTO status update
Vancouver, British Columbia--(Newsfile Corp. - July 4, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") has reported financial results for the year ended December 31, 2021, and an update on...
Jun '22
Emerald Health Therapeutics Provides Bi-Weekly MCTO Status Update
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management...
Jun '22
Emerald Health Therapeutics, Inc. Provides Second Bi-Weekly MCTO Status Update
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") is providing a status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease...
May '22
Emerald Health Therapeutics, Inc. Provides Bi-Weekly MCTO Status Update
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management...
May '22
Emerald Health Therapeutics Signs Arrangement Agreement with Skye Bioscience
Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022
Preclinical studies have demonstrated potential advantages of Skye's unique, patent-protected therapeutic...